
https://www.nature.com/articles/s41443-025-01154-y
Mechanical failure of inflatable penile prostheses: a 2025 snapshot and historical context
Steven K Wilson, John J Mulcahy, Tobias Köhler, Paul Perito, Ahmet Tevfik Albayrak, Alfredo Suarez Sarmiento
International Journal of Impotence Research, 1-5, 2025
Inflatable penile prostheses (IPPs) are the preferred surgical option for men with erectile dysfunction that is unresponsive to medical therapy, offering superior cosmetic and functional outcomes [1]. However, device reliability remains a clinical concern even after 5 decades of usage [2]. For the first 5 months of 2025, the United States (US) Food and Drug Administration’s (FDA) Manufacturer and User Facility Device Experience (MAUDE) recorded 1324 reports of American IPPs removed for adverse events [3].
Boston Scientific (Marlborough, USA) accounted for 586 (44.3%) events, while 738 (55.7%) were linked to Coloplast (Minneapolis, USA)[3]. A PubMed search identified 581 articles that analyzed MAUDE data across a broad range of implants, including cochlear implants [4], devices for benign prostatic hyperplasia [5], guidewires [6], nitinol stents [7], barbed sutures [8], intercranial devices for epilepsy [9], breast implants [10], nasal epistaxis balloons [11], dermal fillers [12], and many more. To the best of our knowledge, however, this is the first study to examine MAUDE reports for IPPs. Given that approximately 2,000 IPPs are placed each month in the US, the monthly number of explant procedures appears disproportionately high relative to the implanted population [3]. A closer analysis of the data is warranted to detect preventable adverse events.